Merck & Co., Inc.
(NYSE: MRK)

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. On July 2, 2014, Santen Pharmaceutical Co., Ltd acquired certain ophthalmology assets from Merck & Co., Inc. On August 5, 2014, Merck & Co Inc (Merck) acquired Idenix Pharmaceuticals Inc (Idenix).

120.680 -

-0.890 (-0.73%)
Range 120.390 - 121.595   (1%)
Open 121.190
Previous Close 121.570
Bid Price 120.640
Bid Volume 60
Ask Price 120.670
Ask Volume 40
Volume 2,305,982
Value 170,602,732
Remark -
Delayed prices. Updated at 19 Feb 2026 01:20.
Data powered by
View All Events

About Merck & Co

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. On July 2, 2014, Santen Pharmaceutical Co., Ltd acquired certain ophthalmology assets from Merck & Co., Inc. On August 5, 2014, Merck & Co Inc (Merck) acquired Idenix Pharmaceuticals Inc (Idenix).

Loading Chart...

Please login to view stock data and analysis